Abstract Tumor cells along with a small proportion of cancer stem cells exist in a stromal microenvironment consisting of vasculature, cancer-associated fibroblasts, immune cells and extracellular components. Recent epidemiological and clinical studies strongly support that vitamin D supplementation is associated with reduced cancer risk and favorable prognosis. Experimental results suggest that vitamin D not only suppresses cancer cells, but also regulates tumor microenvironment to facilitate tumor repression. In this review, we have outlined the current knowledge on epidemiological studies and clinical trials of vitamin D. Notably, we
Tumor microenvironment (TME) is comprised of various stromal cells (e.g., endothelia, cancer-associated fibroblasts, and immune cells) and extracellular components (e.g., cytokines and extracellular matrix), which surround tumor cells and are nourished by a vascular system. The pivotal roles of TME during tumor initiation, progression, and metastasis have been recently reviewed in detail elsewhere 1, 2 . Importantly, TME greatly influences therapeutic efficacy and emerges as a new target for treating tumors [3] [4] [5] . Vitamin D is a multifunctional precursor of the potent steroidal hormone calcitriol (1α,25-dihydroxyvitamin D 3 , 1,25(OH) 2 D 3 ). As most foods contain little vitamin D, there are certain diseases which need vitamin D as a dietary supplement to replenish the deficiency, especially for the elderly and children to maintain adequate vitamin D store for bone health and autoimmunity 6 . Recently, epidemiological and clinical observations strongly suggest that vitamin D deficiency or low circulating 25-hydroxyvitamin D (25(OH)D) level in serum increases the risk of developing multiple malignancies. Experimental evidence also showed that 1,25(OH) 2 D 3 , the active form of vitamin D, can exhibit anticancer actions through different signaling pathways, including inhibition of proliferation, induction of cell apoptosis and differentiation, as well as suppression of metastasis and angiogenesis in various cancers. Notably, vitamin D was found to not only have profound effects on normal cancer cells, but also on cancer-associated stromal cells and cancer stem cells within the TME. Regarding the important role of TME in cancer initiation, progression, metastasis and recurrence, vitamin D might be used as a therapeutic agent targeting the TME to assist clinical treatment and prognosis for many kinds of cancer. Herein, this review summarized the anticancer action of vitamin D in the TME of cancer cells, stroma cells and cancer stem cells. We also outlined the epidemiological studies and clinical trials of vitamin D, providing a better understanding of the role of vitamin D in cancer treatment to re-propose vitamin D as a novel anticancer agent. an inactive form. In fact, the expression of CYP24A1 is highly induced by 1,25(OH) 2 D 3 , which is thus the limiting step of vitamin D activation. CYP24A1 is usually highly expressed in cancer tissues, and CYP24A1-induced vitamin D insufficiency might also promote cancer progression. A study of 99 CRC patients demonstrated that CYP24A1 expression was higher in cancer specimens than paired normal tissue, and high expression level of CYP24A1 strongly correlated with tumor invasion, lymph node metastasis, decreases in overall survival (P ¼ 0.026) and advanced CRC recurrences (P ¼ 0.32) 7 . In addition, Shiratsuchi et al. 8 has recently observed that knockdown of CYP24A1 significantly restrained lung cancer xenograft in vivo, suggesting that CYP24A1 could be identified as a potential oncogene in lung cancer. It was found that a protein kinase CK2 inhibitor, 4,5,6,7-tetrabromobenzimidazole, could enhance the antitumor effect of 1,25(OH) 2 D 3 on prostate cancer through directly inhibiting the CYP24A1 expression 9 . Thus, the inhibition of CYP24A1 expression or activity and exploration of CYP24A1 inhibitors might be a good way to increase the anticancer action of 1,25(OH) 2 D 3 .
Vitamin D signaling
The biological actions of 1,25(OH) 2 D 3 are mainly mediated by vitamin D receptor (VDR) via genomic pathway, although a 1,25(OH) 2 D 3 -induced non-genomic pathway has been identified recently (Fig. 1 ). The binding of 1,25(OH) 2 D 3 to VDR triggers VDR translocation into the nucleus and transcriptionally induces the downstream target genes such as CDKN1A, C-MYC, CDH1, and CYP24A1. Thus, the expression level of VDR in cancers is always associated with vitamin D response. Notably, high VDR expression has been found in many cancer types, such as breast cancer and papillary thyroid carcinoma 10, 11 . There was also a similar trend of CYP27B1 expression in cancers, which could provide a possible explanation for VDR overexpression in cancer cells 12, 13 . High level of VDR expression has been associated with improvement in prognosis of patients with lung, prostate, pancreatic, and colorectal cancers, indicating that VDR expression might be a prognostic biomarker in these cancers [14] [15] [16] [17] . Recently, it was demonstrated that higher expression level in stroma cells in cancer adenocarcinoma could facilitate larger actions for vitamin D, thus improving therapeutic outcome 18, 19 . Moreover, we recently demonstrated that higher expression of VDR was found in gastric cancer tissue than that in normal gastric tissue, and 1,25(OH) 2 D 3 displayed inhibitory effect in gastric cancer cells without influencing normal epithelial cells 20 . Taken together with the current findings, overexpression of VDR in cancer cells and tissues or in surrounding stroma cells would pose an advantage of using vitamin D as an anticancer agent with an enhanced therapeutic window against cancer. However, although VDR expression has a predominant role for vitamin D action, VDR may potentially function as an oncogene. One study reported that knockdown of VDR evidently induced apoptosis in breast and prostate cancer cells 21 , indicating a controversial role for VDR.
Epidemiological studies
The serum concentration of the vitamin D metabolite 25(OH)D is commonly used as the index of vitamin D status in body. In particular, circulating 25(OH)D level in human lower than 20 ng/mL, from 20 to 30 ng/mL, and higher than 30 ng/mL indicate a deficiency, a relative insufficiency and a sufficiency of vitamin D, respectively 22, 23 . Although controversial findings exist, most epidemiological studies have indicated that serum vitamin D status is correlated with multiple types of cancer risk, including colon, prostate, breast, and gastric cancers. Patients with low vitamin D levels are usually diagnosed with poorer survival and higher cancer mortality, suggesting that vitamin D might protect individuals against late stages of carcinogenesis. 27 . A meta-analysis found a significant association between higher 25(OH)D level and increased prostate cancer risk 28 . It seemed that results in prostate cancer were somewhat inconsistent, which might be due to the limitations of selected population and control. Considering that the anticancer action of vitamin D has been well elucidated in prostate cancer cells in vitro and in vivo 29 , more thorough epidemiological studies on vitamin D and prostate cancer risk may be needed.
Breast cancer
The relationship between vitamin D intake and breast cancer susceptibility has been well studied. Pooled analysis on breast cancer supported the inverse correlation between vitamin D and calcium intake and breast cancer risk, while some of the studies showed no association [30] [31] [32] [33] . Although the results are complex and inclusive, it is expected that vitamin D supplement still benefits for breast cancer prevention. In a sectional study, high vitamin D levels significantly improved clinical outcomes in Brazilian postmenopausal women with breast cancer 34 . Moreover, it seemed that the association was stronger in premenopausal vs. postmenopausal women 27, 35, 36 . Recently, a cohort study including 1666 women diagnosed with breast cancer seemed highly convincing. They found that elevations in serum 25(OH)D concentrations were associated with superior overall survival especially among premenopausal women 37 , strongly suggesting the use of serum vitamin D level as a prognostic marker for breast cancer. Moreover, among African American women, data showed that vitamin D deficiency increased breast cancer susceptibility by approximately 23% 38 , indicating vitamin D intake could be consider as a preventive factor for breast cancer incidence.
Colorectal cancer
Epidemiological studies conducted on colorectal cancer (CRC) provided strong support for inverse association between serum 25(OH)D level and colon cancer risk in both men and women [39] [40] [41] [42] . A cross-sectional study indicated that low concentration of 25(OH)D in serum was significantly associated with adenomas or colon polyps 43 . A meta-analysis showed that higher circulating 25(OH)D levels predicted decrease cancer death of CRC patients 44 . indicating that restoration of vitamin D level to normal levels in vitamin D deficient patients might benefit for a better prognosis of CRC. Notably, the association between vitamin D status and CRC risk sometimes varied with multiple factors. For example, a nest case-control study showed that high concentrations of plasma 25(OH)D was correlated with decreased CRC incidence in individuals with intense immune reaction but not that with lower-level immune responses (Odds ratio ¼ 0.10; 95% CI: 0.03 to 0.35; P o 0.001) 45 . 47 . Another study only found prospective evidence in esophageal squamous cell carcinoma (ESCC) but not in gastric carcinogenesis 48 . In a study of 197 gastric cancer patients, the cancer center of Sun Yat-sen University demonstrated that vitamin D deficiency might contribute to decreases in overall survival (P¼0.019) 49 . Until now, the relationship between vitamin D supplements and upper gastrointestinal cancer risk has not been unsubstantiated, and the protective and prognostic role of serum 25(OH)D concentrations need to be further analyzed.
Other types of cancer
Some studies have reported an association of bladder cancer risk with vitamin D insufficiency, suggesting a protective role of vitamin D in bladder cancer [50] [51] [52] . In addition, the incidences of other types of cancer (e.g., lung cancer, ovarian cancer, and melanoma) showed controversial outcomes or indeterminate results between 25(OH)D concentrations and cancer risk, and the association might be varied in different cancers [53] [54] [55] Initial trials of vitamin D have been conducted using its original form. It has been found that 400 IU is the optimal and safe dose of vitamin D for adults to prevent cancers, while high-dose higher than 2000 IU may inversely promote cancer growth in multiple cancer types such as gastric, pancreatic, colorectal and breast cancers 58 . The selection of proper doses might be one of the reasons for the controversial role of vitamin D in cancer prevention and treatment. In one study, vitamin D intake ( Z 400 IU) daily significantly decreased risks of lung cancer among non-smoking participants 59 . However, a clinical trial including 2303 subjects found that vitamin D intake (2000 IU/day) was not associated with lower cancer risk compared with the placebo control group in all cancer types 60 . Furthermore, it is seemed that high dose supplementation of calcium and vitamin D was correlated with undesirable results. For example, daily intake of calcium (1200 mg/day) and vitamin D (1000 IU/day) continuous for 3-5 years could increase the incidence of serrated adenomas in colon among the participants with one or more colon polyps 61 . Clinical trials performed in most cases were supplied with 1,25(OH) 2 D 3 other than vitamin D to achieve the higher serum concentrations, expecting to produce the maximum antitumor effects of 1,25(OH) 2 D 3 . Clinical studies of 1,25(OH) 2 D 3 plus other anticancer drugs such as docetaxel, estramustine, and carboplatin in patients with cancers indicated that the high dose (20 IU/kg) of 1,25(OH) 2 D 3 was safe and well-tolerated [62] [63] [64] [65] . Some of the trials exhibited promising antitumor activity, while some did not. A phase II trial of in androgen-independent prostate cancer with high-dose of 1,25(OH) 2 D 3 (480 IU three days per week) for at least one month plus dexamethasone revealed encouraging antitumor activity 66 . It was demonstrated in a phase II study in advanced pancreatic cancer that 1,25(OH) 2 D 3 might have enhanced activity in combination with docetaxel but not with gemcitabine or erlotinib 67 . However, in another phase II trial of weekly intravenous 1,25(OH) 2 D 3 at dose of 2960 IU in combination with dexamethasone for castration-resistant prostate cancer, no positive outcomes were found 68, 69 . DN-101, a high-dose calcitriol formulation, was developed to increase the bioavailability of 1,25(OH) 2 D 3 . The maximum tolerated dose (MTD) of DN-101 was 1800 IU by weekly oral administration, while hypercalcemia was observed in patients treated at 2400 IU weekly 65 . A phase II study in recurrent prostate cancer, combination therapy with weekly 1,25(OH) 2 D 3 (DN-101, 1800 IU) and daily naproxen was associated with prolonged the PSA doubling time, indicating the encouraging benefit of 1,25(OH) 2 D 3 70 . However, a randomized phase III trial of androgen-independent prostate cancer study of calcitriol enhancing taxotere (ASCENT, DN-101 1800 IU per week) unexpectedly revealed that shorter overall survival was found in 1,25(OH) 2 D 3 treatment group compared to placebo group 71 . Consequently, even when a high dose of 1,25(OH) 2 D 3 was studied, the outcomes were not always promising. In particular, optimization of the dosage of 1,25(OH) 2 D 3 might be critical for effective treatment of cancers. Among the most of these clinically studied analogues is EB1089. This drug (also named as seocalcitol) is characterized by an altered side chain structure featuring 26,27-dimethyl groups and two double bonds. It was synthesized to overcome the side effect of hypercalcemia. EB1089 was shown to inhibit prostate cancer metastasis in vivo with significantly weaker calcemic side effect compared with 1,25(OH) 2 D 3 72 . EB1089 has been shown to induce cell cycle arrest, cell differentiation and apoptosis in various cancer types including colon, prostate, breast and hepatocellular cancer (without hypercalcemia) both in vitro and in vivo [73] [74] [75] [76] [77] . Notably, EB1089 was shown to be more effective than 1,25(OH) 2 D 3 in inducing apoptosis through suppressing BCL-2 and this agent also induced autophagic cell death in breast cancer cell line MCF7 78, 79 . EB1089 was also significantly less calcemic than 1,25(OH) 2 D 3 and exhibited antimetastatic effects on prostate cancer 72 . A phase II clinical study has shown that it was well tolerated at a daily dose of 10-20 μg, which is significantly less calcemic than 1,25(OH) 2 D 3 80 . A phase II study of EB1089 conducted on patients with inoperable hepatocellular carcinoma indicated promising antitumor activity 81 .
Vitamin D analogues
Another less calcemic vitamin D analogue, paricalcitol, was applied in a phase I/II study in advanced androgen-insensitive prostate cancer patients with i.v. receiving paricalcitol at escalating doses of 5 to 25 μg
82
. Serum parathyroid hormone (PTH) level, a common index of advanced prostate cancer, was significantly decreased by paricalcitol, potentiating it as a therapeutic agent for improving cancer outcome. Accordingly, oral paricalcitol was also proved to be associated with low serum PTH level in patients with metastatic breast cancer 83 . Inecalcitol, which has been identified as a VDR antagonist, more effectively activates VDR expression than 1,25(OH) 2 D 3 and exerts much stronger inhibitory effect on prostate cancer 84, 85 . In a phase I study, in metastatic castration-resistant prostate cancer patients, the maximum dose of inecalcitol was 4000 μg per day combined with docetaxel, which showed antiproliferative activity and 100-fold lower hypercalcemic activity than 1,25 (OH) 2 
Vitamin D-related gene polymorphism
Polymorphisms in genes related with vitamin D metabolism, including VDR, CYP27A1, CYP27B1, CYP24A1 and GC, have been associated with cancer risk and progression, and may function as a valuable factor in cancer prognosis. Here, we summarized the epidemiological and genetic studies performed in recent years depicting the association of gene polymorphisms with cancer risk, progression and prognosis in Table 2 57, . A meta-analysis revealed that Bsm I, Apa I, Fok I and Poly (A) polymorphisms in VDR gene might be related to breast cancer progression 114 . Another study which involved 3336 incident primary melanoma cases found that VDR single nucleotide polymorphisms (SNPs), rs1544410/Bsm I and rs731236/Taq I, significantly correlated with melanoma survival among subjects exposed to high UVB 117 . A case-control study including 528 CRC patients and 605 cancer-free controls and a follow-up study with 317 cases, which were conducted in northeast China, suggested that two polymorphisms in CYP27B1 (rs10877012 and rs4646536) are associated with decreased CRC risk while CYP24A1 (rs4809957) polymorphism might lead to a worse prognosis of CRC 94 . It was also reported that the CYP24A1 variant rs964293 modulated the association between combined oestrogenprogestogen (EþP) hormone therapy and CRC risk, suggesting the important role of CYP24A1 polymorphism in cancer progression 97 . Equal importantly, GC polymorphisms might be a predictive marker for outcome of chemotherapies. AA genotypes of GC rs4588 polymorphism was strongly associated with longer overall survival in CRC patients with treatment of irinotecan/ cetuximab, whereas treatment with irinotecan/bevacizumab were associated with the converse 103 . These data support the use of specific gene polymorphisms as potential markers for cancer risk and cancer mortality.
Mechanisms of action of vitamin D within the tumor microenvironment
The antitumor activity of 1,25(OH) 2 D 3 , the active form of vitamin D, has been widely studied in a number of cancer types. By binding to VDR, 1,25(OH) 2 D 3 exerted antitumor efficacy through regulating target gene expression or nongenomic actions related to different signaling pathways in both normal cancer cells and cancer stem cells. The anticancer actions of 1,25(OH) 2 D 3 include the induction of cell cycle arrest, cell differentiation, cell apoptosis, autophagic cell death, as well as inhibition of metastasis tumor angiogenesis. Importantly, vitamin D could modulate stromal cells to suppress tumor angiogenesis, progression and metastasis in TME. Recent studies also demonstrate an anti-inflammatory role of vitamin D within TME. The schematic illustration of mechanisms related to the anticancer action of vitamin D within the TME is shown in Fig. 3. 3.1. Tumor cells 3.1.1. Regulation of proliferation 1,25(OH) 2 D 3 has been found to inhibit cell proliferation through cell cycle arrest in most cancer cells, which plays an important role in cancer prevention 76 . The effect of 1,25(OH) 2 D 3 on cell cycle distribution was mainly dependent on induction of p21 and p27 expression. p21 and p27 were identified as the targets of 1,25(OH) 2 D 3 and were critical for G1 phase cell cycle arrest and inhibition of cancer cell proliferation 120, 121 . It was reported that the activation of JNK and ERK1/2 MAPK signaling pathways by 1,25(OH) 2 D 3 were required for the induction of p21 expression 122 . Notably, p53 was involved in the regulation of p21 by 1,25(OH) 2 D 3 . There were multiple binding sites for p53 located in the promoter of p21 to cooperate with VDR to regulate transcriptional activity of p21 120 . We recently found that 1,25(OH) 2 D 3 can induce p21expression and G1 phase cell cycle arrest in a mutant p53 and VDR dependent manner in gastric cancer cells 20 . At the meantime, p27 could up-regulated by 1,25(OH) 2 D 3 , although no canonical VDR element (VDRE) was identified in the p27 promoter 123 . It is demonstrated that VDR could not directly bind to the p27 promoter but interacts with sp1 to regulate the promoter activity of p27 123 . Also, 1,25(OH) 2 D 3 up-regulated p27 expression through inhibition of Thr187 phosphorylation-dependent degradation in prostate cancer and increase the stability of p27 through down-regulation of ubiquitin pathway in ovarian cancer. 124, 125 Furthermore, some other cyclindependent kinase inhibitors such as p15 and p16 may be induced by 1,25(OH) 2 [135] [136] [137] [138] . In in vitro studies, it has been reported that vitamin D, in synergy with cisplatin, the histone deacetylase inhibitor trichostatin A, sodium butyrate or the methylation inhibitor 5-aza-2 0 -deoxycytidine, could induce apoptosis in gastric cancer cells 139, 140 . This indicated that 1,25(OH) 2 D 3 , the normal dietary supplement, could be considered for combination treatment for cancer.
Induction of differentiation
Induction of differentiation has been reported to involve in 1,25(OH) 2 D 3 -induced cancer suppression. 1,25(OH) 2 D 3 is considered as a differentiating agent for leukemia cells. It could promote myeloid leukemia cells differentiating into mature myeloid cells, and has been used in clinical trials for acute myeloid leukemia 141, 142 . Furthermore, 1,25(OH) 2 D 3 can induce differentiation in cancer cells, mostly in colon cancer, through repression of WNT/β-catenin signaling. Activation of WNT/β-catenin signaling is commonly found in colon cancer, and is associated with undifferentiated properties and malignance of cancers 143 . 144 . It was also found that 1,25(OH) 2 D 3 inhibited WNT/β-catenin signaling through induction of E-cadherin and the WNT inhibitor DKK1 in colon cancer cells, functioning as a multilevel suppressor of WNT/β-catenin signaling pathway [145] [146] [147] [148] [149] . E-cadherin is associated with epithelial phenotype of cancer cells and loss of E-cadherin causes invasiveness of cancer cells. Induction of E-cadherin and other differentiated epithelial marker ZO-1 by 1,25(OH) 2 D 3 and inhibition of WNT/β-catenin downstream targets such as c-Myc and cyclin D finally restrain the cancer cell differentiation, which is also associated with tumor angiogenesis, migration and invasion.
Inhibition of angiogenesis and metastasis
The vitamin D signaling pathway is also associated with tumor angiogenesis, which is one of the mechanisms contributing to the anticancer action of 1,25(OH) 2 D 3 . Vascular endothelial growth factor (VEGF) is a growth factor that stimulates the formation of blood vessels, and its overexpression in cancer cells promotes angiogenesis and metastasis 150 . Suppression of hypoxia-inducible factor 1 (HIF-1α)-mediated VEGF expression and signaling by 1,25(OH) 2 D 3 was detected in many kinds of cancer cells including prostate, breast and colon cancers 151, 152 . NF-κB signaling, the nuclear protein Forkhead box M1 (FOXM1) and DKK4 have been suggested to mediate the anti-angiogenesis effects of 1,25(OH) 2 D 3 . It was found that 1,25(OH) 2 D 3 inhibited angiogenesis through reduction of NF-κB mediated interleukin-8 (IL-8) secretion in prostate cancer cells 151 . Treatments with 1,25(OH) 2 D 3 or the vitamin D analogue EB1089 or activation of VDR remarkably suppressed pancreatic ductal adenocarcinoma cells proliferation, self-renewal abilities and metastasis through down-regulation of FOXM1. The latter is an oncogene that plays a key role in cell cycle regulation and carcinogenesis 153 . In addition, DKK4, a known downstream target of vitamin D signaling and an inhibitory Wnt ligand, was reported to inhibit tumor angiogenesis, migration and invasion in colon cancer cells in vitro. These findings further support the anti-angiogenesis and antiinvasiveness roles for vitamin D in cancer prevention 147 . Finally, 1,25(OH) 2 D 3 also suppressed epithelial-mesenchymal transition of SKOV-3 ovarian cancer cells through reduction of Slug and Snail and upregulation of E-cadherin, thus resulting in the inhibition of migration and invasion of SKOV-3 cells 154 .
Induction of autophagy
Induction of autophagy by vitamin D was initially studied in the immune system. Vitamin D can induce autophagy in many kinds of immune cells through the host defense peptide LL37 for bacteria eradication. Accumulating evidences (best substantiated in breast cancer) indicates that vitamin D, as well as its analogue EB1089, suppresses cancer progression through autophagicinduced cell death. Initially, it was found that EB1089 triggers massive autophagy in MCF-7 breast cancer cells by upregulating the tumor suppressor gene Beclin-1, thereby inducing breast cancer cell death 79 . Recent evidence showed that the vitamin Dinduced autophagic effect was found specifically in luminal-like breast cancer cells and benefited a lot in combination with hydroxychloroquine (HCQ), an inhibitor of autolysosome acidification for suppression of breast cancer growth in vivo 155 . Studies also indicated that the autophagy produced by either vitamin D or its analogue EB1089 could also modulate radiation sensitivity in breast cancer and non-small cell lung cancer (NSCLC) cells. Vitamin D or EB1089 increased radiation efficiency through promotion of autophagy in p53 existing breast cancer 156 and NSCLC cells 157 but not in p53-null cells, which indicates an important role of p53 in vitamin D-induced autophagy. Above all, vitamin D functions as an autophagic switch in human health maintenance and various types of cancer resistance, providing a novel perspective by magnifying the radiation responses in human malignancies.
3.1.6. Nongenomic effect Nongenomic actions of 1,25(OH) 2 D 3 are rapid and not dependent on VDR-mediated transcriptional activation (Fig. 2) , recently reviewed by Hii and Ferrante 158 . The most well-established nongenomic effect of 1,25(OH) 2 D 3 is the rapid intestinal absorption of Ca 2þ . It has been demonstrated that alteration of intracellular Ca 2þ homeostasis is associated with tumor initiation, angiogenesis, progression and metastasis 159 . Based on this, a new mechanism of 1,25(OH) 2 D 3 in regulation of E-cadherin has been found in colon cancer cells. Rho-ROCK-p38MAPK-MSK1 activation was mediated by 1,25(OH) 2 D 3 -induced upregulation of cytosolic Ca 2þ concentration ([Ca 2þ ] cyt ), which was required for genes expression of CYP24A1 and E-cadherin 160 . In squamous cell carcinoma cells, 1,25(OH) 2 D 3 provoked apoptosis through the rapid nongenomic activation of PI3K/Akt/ERK1/2/MAPK signaling and inhibition of the anti-apoptotic protein cIAP and XIAP 161 . These findings dual actions of VDR and expands the understanding that the nongenomic activation of VDR might synergize with the VDR-dependent genomic pathway to produce antitumor effect of 1,25(OH) 2 D 3 .
Stromal cells
The tumor stroma cell is one important part of developing tumor microenvironment, promoting expansive proliferation, metastatic capacities and chemoresistance of solid tumors. Stroma cells contain many cell types including epithelial cells, tumorassociated fibroblast, tumor-derived endothelial cells and infiltrating immune cells. More and more studies show that different stromal cells types in tumor microenvironment influence a lot of hallmarks of cancer. For example, endothelial cells trigger tumor angiogenesis, while cancer-associated fibroblasts (CAFs) are involved in activating tumor invasion and metastasis, proliferation and in resisting cell death 162, 163 . Emerging evidence suggests that vitamin D participates in modulating the gene signature of tumor stroma cells to regulate tumor angiogenesis, progression, and metastasis. Such findings suggest that vitamin D is a promising therapeutic for cancer. comparable to those required to suppress cancer cells 152, 164 . Recently, emerging evidence showed that 1,25(OH) 2 D 3 repressed tumor angiogenesis in some in vivo models such as the TRAMP-2 prostate tumor models and breast cancer models. 1,25(OH) 2 D 3 inhibited TDECs in TRAMP-2 tumor with wild-type VDR but not in VDR knockout mice and enhanced tumor blood vessel density in VDR-knockout mice when compared with tumors from wild-type mice 165 . These results indicate the importance of VDR signaling on TDECs in the regulation of prostate cancer angiogenesis. It should be noted that 1,25(OH) 2 D 3 could induce apoptosis of VEGF sprouting endothelial cells, thereby decreasing the blood vessel density in breast cancer xenograft tumors 152, 166 . Therefore, 1,25(OH) 2 D 3 may function as an important regulator in alteration of pathologic angiogenesis to regulate the tumor microenvironment. 19 . In a recent report, the activation of vitamin D signaling pathway in pancreatic CAFs suppressed the transmission of certain exosomal oncomiR such as miR-10a-5p from CAF to PC cells and thus diminished its protumoral effects on PC cells 167 , which provided a new perspective on how vitamin D regulates CAFs. Furthermore, it is reported that 1,25(OH) 2 D 3 exhibited protective effect against CRC through inhibiting CAFs independently of VDR expression in CRC cells, while higher VDR expression in CAFs predicted longer overall survival in CRC patients 168 . Although promising results have been achieved on the regulation of CAFs by vitamin D, the underlying mechanisms remain to be evaluated, especially in different cancer types.
Cancer-associated fibroblast

Tumor-infiltrating lymphocyte
Recently, a number of clinical and preclinical studies showed that tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment play a significant role in cancer progression or tumor suppression and may be identified as a new therapeutic target for cancer treatment. Effects of vitamin D on immune cells has been well studied, especially in host defense against bacteria such as the clearance of Mycobacterum tuberculosis. It was reported that the antibacterial activity of vitamin D on M. tuberculosis was mediated by autophagy through the upregulation of LL37 and the activation of Beclin-1 and ATG5 in monocytes and macrophage 169, 170 . Vitamin D supplements promoted INF-γ related antimicrobial effects of human macrophages 171 . On the other hand, vitamin D plays a significant role in adaptive immunity, and vitamin D deficiency might disrupt CD8 effector differentiation and the response of memory CD8 T cells for viral or bacterial infection in mice 172 . It was also found that vitamin D-induced tolerogenic dendritic cells (DC) increased population of CD4 . Moreover, vitamin D induced regulatory T cell (Treg/Th17) differentiation through TGF-β signaling in a VDR-dependent manner, which indicated that vitamin D uptake might benefit for organ transplantation recipients 174 . Sun et al. 175 found that vitamin D could modulate IL-17 and RANKL expression through VDR-mediated NF-κB signaling, resulting in the inhibition of Th17 cell differentiation in both in vitro and mice models. and had favorable immune responses including promoting T-cell blastogenesis and HLA-DR expression 178 . As the functional role of vitamin D in cancer immunotherapy is still limited, more studies on vitamin D in anti-cancer immunity are needed. Since cancer immunotherapy is now becoming a hot topic and benefits increasing number of cancer patients worldwide, it is expected that vitamin D might enhance cancer immunoprevention and increase the activity of immune cells to kill cancer cells.
Cancer stem cells
Cancer stem cells (CSCs) or tumor initiating cells (TICs) are critically responsible for tumorigenesis, progression, metastasis, and tumor recurrence, but they account for only a small proportion of cancer cells. Regarding the important role of the low-proportion CSCs in cancer microenvironment, targeting CSCs might be an efficient and promising method for cancer suppression. Recent studies have demonstrated that vitamin D may suppress cancer progression through targeting CSCs compartment. The role of vitamin D in regulating CSCs in gastrointestinal cancers has been thoroughly reviewed in our previous report 179 . Here 181 . In mammosphere, OCT4 and KLF4, which is associated with stem cell self-renewal and undifferentiated phenotype, were reduced by 1,25(OH) 2 D 3 or BXL1024 182 . It is reported that another vitamin D analogue EB1089 in cooperation with BRAC1 exhibited anti-mammosphere formating ability in breast cancer cells 183 . Notably, Jeong et al. 184 found that 1,25(OH) 2 D 3 or oral administration with vitamin D could inhibit mouse TICs in MMTV-WNT1 mammary tumors through WNT/β-catenin signaling in vivo. 1,25(OH) 2 D 3 inhibited spheroids formation of mouse TICs in 3D tumor spheroid culture assay in vitro 184 . However, some studies showed that VDR was down-regulated in breast cancer mammosphere, potentially indicating less vitamin D action on breast CSCs 183, 185 . Despite the controversy, the current findings still provided a new strategy for vitamin D targeting breast CSCs and give us a deeper understanding of vitamin D effect in cancer.
Although the anticancer effect of vitamin D on prostate cancer cells has been widely explored both in vitro and in vivo, the exact pharmacological action of vitamin D on prostate CSCs is not well understood. Existing evidence showed that the mechanism involved in the regulation of prostate CSCs by vitamin D was partly similar to that of prostate cancer cells. Maund et al. 186 demonstrated that 1,25(OH) 2 D 3 could induce p21 and p27 expression as well as cell cycle arrest in mouse prostate CSCs, and its anti-proliferative effect was mainly mediated by upregulation of IL-1α. In addition, the micro-array data indicated that the CSCs signaling (e.g., BMP and TGF-β) participated in the regulatory action of 1,25(OH) 2 D 3 on prostate CSCs 186 . Taken together, the mechanisms underlying vitamin D regulation of CSCs seem similar to that of normal cancer cells, i.e., mainly through WNT/β-catenin, BMP, Notch and TGF-β signaling mechanisms.
Inflammatory mediators
Inflammation plays an important role in tumorigenesis 187 . Studies have indicated that vitamin D exhibits anti-inflammatory effects within TME to inhibit cancer initiation and progression 188 . Animal studies showed that dietary supplement of vitamin D significantly decreased colon cancer incidence in mice, which might be due to the decrease of MAPK and NF-κB signaling as well as the reduction of pro-inflammatory cytokines in colonic epithelial cells 189 . It is reported that 1,25(OH) 2 D 3 may restrain inflammatory progression through downregulation of MMP-3, INOS and COX-2 levels and upregulation of inflammatory mediators including IL-1β, IL-6, IL-8, and prostaglandins (PGs) in macrophage 190, 191 . COX-2 is involved in pathogenesis of many inflammatory diseases 192 , and 1,25(OH) 2 D 3 is able to decrease COX-2 expression in many kinds of cancers such as breast cancer, colon cancer, ovarian cancer and prostate cancer, thereby suppressing cancer growth [193] [194] [195] [196] . In a clinical trial, higher levels of vitamin D were correlated with lower COX-2 level in prostate cancer cells and stroma cells 197 . Moreover, inflammatory factors including TNF-α, IL-6 and IL-8 were significantly inhibited by 1,25(OH) 2 D 3 in prostate primary epithelial cells, indicating the beneficial role of anti-inflammatory action of vitamin D in prostate cancer 197 . Above all, vitamin D exerts anti-inflammatory effects through suppression of the production and action of inflammatory mediators such as cytokines, chemokines and PGs, and inhibition of MAPK and NF-κB signalings in cancer cells, macrophages as well as the epithelial cells, all of which might contribute to the prevention of cancer progression and inflammatory progress.
Conclusions/perspectives
Accumulating evidence strongly supports the notion that vitamin D deficiency is associated with elevated cancer risk and poor prognosis. Vitamin D supplementation can exert profound suppression of cancers, in particular via targeting components of the TME. Importantly, the emerging role of vitamin D in the regulation of the TME provides a mechanistic basis for its potential efficacy in treating cancer. Although the preclinical and epidemiologic data are persuasive and provide supportive evidence for continued development of vitamin D or its analogues for cancer therapy, no well-designed clinical trial of vitamin D has been carried out. In particular, the optimum dosage of vitamin D supplementation to reduce cancer risk or treat cancer is still unclear. Future clinical trials that treat cancer patients with suitable doses of vitamin D, or new analogues as well as combination therapy may finally demonstrate the promise for use of a classical vitamin with low and known toxicity in humans. Such results may lead to the development of an effective medicine for the prevention and treatment of malignancies in an economical and efficient manner.
